Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 938

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 6
Chunk 938
---
4 we
raised money through our then existing At The Market Offering Agreement, or the 2022 ATM Agreement, with H.C. Wainwright & Co., LLC,
or Wainwright. In October 2024, the S-3 registration underlying our At The Market Offering Agreement expired and the ATM was cancelled.

Financings During the Fiscal Year Ended March
31, 2025:

During the fiscal year
ended March 31, 2025, we raised aggregate net proceeds of $7,746,311, net of $405,002 in commission and legal expenses to Maxim and
$753,090 in direct legal and accounting fees. This total included $3,539,907 from a public offering in May 2024 and $2,054,940 from
subsequent exercise of Class A and Class B warrants and $2,151,464 in net proceeds from a warrant inducement offering in March 2025.
In connection with that transaction, we paid the placement agent fees totaling $153,979, consisting of a 6% commission on gross
proceeds of $138,979 and $15,000 for legal and out-of-pocket expenses to Maxim and $10,877 in direct legal fees.

On
March 16, 2025, Aethlon Medical, Inc. (the “Company”) entered into a
inducement offer to exercise existing Class A and Class B Warrants (the “Agreement”) with a certain accredited and
institutional holder (the “Holder”) of the Company’s outstanding Class A and Class B Warrants issued on May 17,
2024 (the “Existing Warrants”). Pursuant to the Agreement, the Holder, upon exercise, will receive a new unregistered
Common Stock Purchase Warrant (“New Warrant”) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended
(“Securities Act”), to purchase up to a number of shares equal to 200% of the number of Warrant Shares issued pursuant
to the exercise of Existing Warrants pursuant to this Agreement (the “New Warrant Shares”), which New Warrant shall have
an exercise price per share equal to $0.3736, subject to adjustment as provided in the New Warrant, will be exercisable at any time
on or after six (6) months from the date of issuance and have a term of exercise of five and one-half (5.5) years from the date